-
Structures of Parkinson’s disease-linked proteins offer a framework for understanding how they work together
12/21/2023
See how researchers at St. Jude Children’s Research Hospital used cryo-electron microscopy to solve structures of the LRRK2/Rab29 complex, showing potential routes for drug treatment against Parkinson’s disease
-
GPCR structure: Research reveals molecular origins of function for a key drug target
12/21/2023
St. Jude researcher Madan Babu with Brian Kobilka, Michel Bouvier, and Franziska Heidenreich probe the individual contribution of each amino acid in G-protein coupled receptor which binds adrenaline to expand understanding of top drug target
-
Unraveling predisposition in bilateral Wilms tumor
12/18/2023
Learn how scientists at St. Jude gained new understanding of the genomic events that predispose children to bilateral Wilms tumor, cancer in both kidneys.
-
Prediabetes treatment may reduce heart and kidney risks in childhood cancer survivors
12/13/2023
Childhood cancer survivors have a higher prevalence of prediabetes & diabetes than peers. Learn how treating these conditions may protect heart & kidney health.
-
James R. Downing, MD, recognized as one of Modern Healthcare’s 100 Most Influential People for the second consecutive year
12/02/2023
James R. Downing, MD, listed as one of 100 influential people in healthcare in 2023.
-
Modular chimeric cytokine receptors improve CAR T–cell therapy for solid tumors
11/30/2023
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
-
St. Jude revealed functional targets of oncogenic HOXA9 in high-risk pediatric leukemia
11/28/2023
St. Jude scientists identified 229 genes regulated by undruggable oncogenic HOXA9. Learn how it may lead to better treatments for high risk pediatric leukemias.
-
Promising target for CAR T Cells helps cancer trick the immune system
11/21/2023
GRP78 is a promising CAR T-cell immunotherapy target for brain and solid tumors. Discover why it’s special, including how cancer uses it to trick immune cells.
-
Robust chromatin map explains heterogeneity of pediatric acute lymphoblastic leukemia
11/20/2023
Find how mapping chromatin accessibility & regulation in pediatric acute lymphoblastic leukemia (ALL) subtypes may uncover therapy response heterogeneity cause.
-
St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing
11/15/2023
Discover how T-cell differentiation nodes can be promoted or blocked to improve immunotherapy anticancer efficacy according to new T-cell exhaustion research.
-
Fusion oncoprotein forces cell fates toward rhabdomyosarcoma
11/15/2023
Fusion positive pediatric rhabdomyosarcoma (RBD) can come from non-muscle cells with a fusion oncoprotein. Find how the St. Jude discovery may change treatment.
-
‘Highly cited’ St. Jude scientists named to annual list
11/15/2023
Learn more about the St. Jude scientists who are among the most highly cited researchers in the world, a distinction that reflects the value of their work among other investigators.
-
Giles Robinson, M.D., named director of the Neuro-Oncology Division at St. Jude Children’s Research Hospital
11/07/2023
Dr. Robinson is now also co-leader of the Neurobiology and Brain Tumor Program in the St. Jude Comprehensive Cancer Center.
-
Scientists reveal structures of neurotransmitter transporter
11/01/2023
See how researchers at St. Jude Children’s Research Hospital used cryo-electron microscopy to solve structures of a neurotransmitter (dopamine, serotonin) transporter VMAT2 responsible for packing vesicles in neurons for signaling.
-
St. Jude Children’s Research Hospital, ALSAC announce new board leaders
10/16/2023
The boards of St. Jude and ALSAC have new chairs and vice-chairs who will oversee the bold commitments of the ongoing strategic plan.
-
3D genome architecture influences SCID-X1 gene therapy success
10/06/2023
Lentiviral gene therapy for X-linked severe combined immunodeficiency disorder (SCID-X1) is safe. Discover how 3D DNA structure explains biology & safety.
-
Genetics help explain childhood cancer survivors’ mortality risk from a second cancer
10/02/2023
Childhood cancer survivors are at higher risk for second cancer & associated mortality. Find how genetic variants increase risk & can be used to protect health.
-
Predicting phase separation of cancer-causing fusion oncoproteins with machine learning
09/28/2023
See how machine learning was used to gain insight into condensation behavior and oncogenic mechanisms of fusion oncoproteins.
-
St. Jude Children’s Research Hospital Unveils The Domino’s Village
09/27/2023
St. Jude partners with Domino's to build a six-story building for patients and families. The multimillion-dollar housing facility is part of Domino's 10-year commitment to St. Jude.
-
St. Jude refines definition and hones treatment of hyperdiploid leukemia
09/20/2023
Hyperdiploid B-cell acute lymphoblastic leukemia has evaded a consensus definition. Find the definitions that best correlated with better patient outcomes.
-
Specialized T cells in the brain slow progression of Alzheimer’s disease
09/07/2023
T cells can slow Alzheimer’s disease progression in a model system. Find how the neuro-immune study may be the future of neurodegenerative disease research.
-
St. Jude Children’s Research Hospital announces more than $50 million in funding for employee-generated transformational projects
08/30/2023
St. Jude has announced funding for employee-generated ideas. Find out about the approved projects
-
St. Jude shows cancer resistance protein can have its cake and eat it too
08/18/2023
See how one protein responsible for chemotherapy resistance functions and how we can prevent future drug resistance to improve treatment
-
Immune cells present long before infection predict flu symptoms
08/17/2023
Who will get sick from influenza infection has long been a mystery. Learn how immune cells may predict susceptibility to symptoms long before flu infection.
-
St. Jude names Sarah Currie chief nursing executive and senior vice president
08/07/2023
Award-winning NICU expert spent 21 years at Children’s Wisconsin, 4 years as executive director of perinatal/ neonatal services.
-
Mutation accessibility fuels influenza evolution
07/28/2023
See how a new model developed by St. Jude scientists looking at influenza evolution can predict future virus mutations.
-
Jinghui Zhang, PhD, elected Fellow of the International Society for Computational Biology
07/27/2023
Zhang is one of 15 other scientists being honored by ISCB in 2023.
-
Pediatric Early Warning Systems save lives in Latin American hospitals
07/08/2023
Learn how Pediatric Early Warning Systems save the lives of children with cancer in Latin America by identifying early when they are in need of supportive care.
-
Pediatric hepatoblastoma model hints at DNA damage repair pathway for novel therapeutics
07/07/2023
See how creating a new research model to study hepatoblastoma (liver cancer) gave St. Jude scientists clues into potential therapeutic targets
-
Immune and tumor cell “tug-of-war” controls anti-cancer activity
07/05/2023
Cancer cells & the immune cells that activate the anti-cancer response compete over the nutrient glutamine. Discover how it may improve cancer therapies.
-
Base editing shows potential superiority for curing sickle cell disease
07/03/2023
Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Find how St. Jude & Broad are advancing to a cure.
-
St. Jude in top five of elite ranking of hospitals treating children with cancer
06/21/2023
The U.S. News Best Children’s Hospitals for Cancer rankings rely on clinical data and on an annual survey of pediatric specialists.
-
Biostatistician Deo Kumar Srivastava, Ph.D., named ASA fellow
06/20/2023
He is being recognized by the American Statistical Association for his leadership role in numerous St. Jude survivorship studies.
-
Victor J. Torres, Ph.D., named chair of newly formed Department of Host-Microbe Interactions at St. Jude Children’s Research Hospital
06/12/2023
Dr. Victor J. Torres is leading a newly-formed department called the St. Jude Department of Host-Microbe Interactions, which will focus on treating and preventing disease-causing infections in children.
-
Damon Runyon launches new pediatric cancer fellowship in partnership with St. Jude Children’s Research Hospital
06/08/2023
$9 million initiative addresses shortage of top young scientists entering pediatric cancer research careers.
-
St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases
06/01/2023
NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
-
Genetic change increased bird flu severity during U.S. spread
05/30/2023
Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
-
SWI/SNF complexes “bookmark” cell identity during division
05/24/2023
Read about how Scientists at St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
-
Epigenetic landscape modulates pioneer transcription factor binding
05/24/2023
St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
-
Capturing transporter structure paves the way for drug development
05/23/2023
Learn how St. Jude scientists captured six new structures of the Spns2 transporter, providing insights to aid therapeutic design for cancer and other diseases.
-
St. Jude scientist M. Madan Babu elected to the Royal Society of London
05/10/2023
Director of the St. Jude Center of Excellence for Data-Driven Discovery named a fellow of the 360-year-old British scientific organization.
-
St. Jude tool gets more out of multi-omics data
05/04/2023
NetBID2 finds hidden drivers by extracting more from multi-omics data. Learn how the computational tool can find druggable targets in cancer and other diseases.
-
Study shines light on impact of environment on neurocognitive outcomes
04/28/2023
Find how the neighborhood economic hardship index predicts baseline and long-term outcomes in pediatric brain tumor patients treated with radiation therapy.
-
Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma
04/18/2023
Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
-
Prime editing shows proof of concept for treating sickle cell disease
04/17/2023
Genomic prime editing, a new DNA-changing technology, fixed sickle cell disease mutations in patient cells. Learn how it could lead to cure for genetic anemias.
-
St. Jude scientists to receive coveted awards at AACR annual meeting
04/11/2023
Two St. Jude investigators will receive awards at the 2023 AACR meeting. Learn about their careers & the science they & their St. Jude peers will be sharing.
-
Combination therapy overcomes BET inhibitor resistance
04/10/2023
St. Jude scientists found that combination of BET and GSK3 inhibitors can overcome treatment resistance in a type of childhood leukemia. Read about the study.
-
Healthy lifestyle associated with reduced mortality risk in childhood cancer survivors
04/05/2023
A report from the Childhood Cancer Survivor Study (CCSS) provides strong evidence of the importance of a healthy lifestyle for adults who were treated for cancer as children
-
Humans vs. Bacteria: Differences in Ribosome Decoding Revealed
04/05/2023
St. Jude scientists found that human ribosomes decode mRNA slower but more accurately than bacteria. Read about the study’s implications for drug development.
-
St. Jude tool targets cancer-causing fusions’ weak spot
04/05/2023
Learn how St. Jude research cataloguing the oncogenic fusions in pediatric acute myeloid leukemia (AML) could lead to cures using genome editing (CRISPR-Cas9).
-
Greg Armstrong, M.D., MSCE, named Chair of the Department of Epidemiology and Cancer Control at St. Jude Children’s Research Hospital
04/04/2023
National leader in the field of childhood cancer survivorship will spearhead research and advancements.
-
Method for improving seasonal flu vaccines also aids pandemic prediction
03/29/2023
Influenza (flu) vaccines and pandemic predictions can be improved; learn how St. Jude scientists found impactful hemagglutinin mutations contributing to both.
-
Integrated structural biology provides new clues for cystic fibrosis treatment
03/22/2023
Learn about how the cystic fibrosis transmembrane conductance regulator works and how findings from St. Jude will help therapeutic development.
-
Kevin Krull, Ph.D., promoted to chair of the Department of Psychology and Biobehavioral Sciences
02/28/2023
The renamed department will investigate the biological mechanisms underlying the effects of catastrophic disease on the brain.
-
St. Jude approach prevents drug resistance and toxicity
02/27/2023
Explore how St. Jude scientists overcame drug resistance and drug toxicity, using X-ray crystallography to avoid the detoxification pregnane X receptor (PXR).
-
Octavio Ramilo, M.D., named chair of the Department of Infectious Diseases at St. Jude Children’s Research Hospital
02/16/2023
Internationally renowned expert will focus on growing St. Jude into a global leader in infectious diseases research.
-
St. Jude expands patient education resource on childhood cancer
02/15/2023
This free online resource of information and education for families facing childhood and adolescent cancer has a truly global reach.
-
A molecular ticket to ride: St. Jude scientists capture the cellular train that enables transport in cilia
02/13/2023
Find out how Scientists at St. Jude solved the 3D structure of a cellular train in cilia, IFT-A, at nearly ten times the resolution of previous efforts.
-
Access matters: lack of resources is associated with increased mortality in childhood cancer survivors
02/10/2023
Find how increased mortality in childhood cancer survivors is independently associated with local resource deprivation and certain chronic health conditions.
-
Detect minor clones in blood cells: St. Jude looks deep to find source of accelerated aging in childhood cancer survivors
02/08/2023
Explore how deep sequencing childhood cancer survivors found the mutational fingerprint of a toxic chemotherapy associated with a marker of accelerated aging.
-
St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
02/02/2023
Discover how chimeric antigen receptors (CARs) with a new anchor domain increased anti-cancer activity of cellular immunotherapies in cancer models.
-
Thirumala-Devi Kanneganti, Ph.D. named 2022 AAAS Fellow
01/31/2023
Immunologist recognized for her achievements in innate immunity, developing new concepts in inflammasome biology, inflammatory cell death.
-
Catherine Corbin named chief business innovation officer at St. Jude
01/30/2023
Expert in human-centered design to lead new St. Jude department focused on advancing strategic plan.
-
St. Jude names leading researcher as new chair of oncology department
01/26/2023
Julie R. Park, M.D., to succeed longtime chair Ching-Hon Pui, M.D.
-
Pioneering approach advances study of CTCF protein in transcription biology
01/25/2023
Scientists at St. Jude used an innovative degradation system on CTCF, learning more about this protein’s role in transcription. Read about the findings.
-
St. Jude Children’s Research Hospital unveils 45,000-square-foot Family Commons
01/23/2023
Made possible by a $50 million donation from AbbVie, Family Commons is a space for patients and their families to relax and gather in between clinic appointments.
-
Structural insights reveal how SPOP protein contributes to cancer
01/23/2023
St. Jude scientists have captured the 3D structure of the SPOP protein, revealing how it contributes to cancer. Read about the implications for therapeutics.
-
Pharmacotyping of childhood leukemia provides a blueprint for ‘true precision medicine’
01/05/2023
St. Jude scientists performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response.
